The Survival And Its Prognostic Factors Of Patients With Stage ? Non-small Cell Lung Cancer Receiving Thoracic Radiotherapy

Objective: To explore the survival and prognostic factors of thoracic radiotherapy in patients with stage IV NSCLC.Materials and methods: Clinical data for 63 stage IV NSCLC patients with thoracic radiotherapy from 2009.1 to 2014.6 were collected and prognostic factors were analyzed. Kaplan-Meier was used for univariate analysis and Cox regression for multivariate analysis of survival analysis.Results: The local response rate was 79.4%. The 1-, 2- and 3-year survival rates(OS) of the whole group were 43.6%, 21.1% and 14.0% respectively with a median survival is 11 months. Univariate analysis showed KPS score(P=0.040), single organ metastasis(P=0.009), radiation dose to the primary tumor?60Gy(P=0.008) and receiving ?4 cycles of chemotherapy(P<0.001) were positive factors for OS. In multivariate analysis, single organ metastasis,receiving a radiation dose to the primary tumor ?60Gy and receiving ?4 cycles of chemotherapy were the independent positive factors for OS. Two patients(3.2%) had grade 2 radiotion esophagitis, 3 cases(4.8%) had grade 3 radiation pneumonia and 1 case(1.6%) grade 4 radiation pneumonia. Eleven patients(17.5%) had grade 3 or 4 blood toxicity. No treatment related death was observed.Conclusion: Thoracic radiotherapy can improve the survival time of patients with stage IV non-small cell lung cancer. Single organ metastasis, thoracic radiation dose ?60Gy and ?4 cycles chemotherapy can prolong survival time.